Xeris debuts Gvoke HypoPenGvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle. FDA approves Rukobia for HIVViiV Healthcare's Rukobia is a treatment for patients with multidrug-resistant HIV infections. Upsher-Smith offers help to people with migraines during Migraine Month Upsher-Smith's Access Pathways Program offers patient savings and support services for patients who need migraine medications. Novartis receives FDA nod for new indication of Cosentyx The indication to treat non-radiographic axial spondyloarthritis is the fourth FDA-approved indication for Novartis’ Cosentyx. Abbott gets FDA clearance for FreeStyle Libre 2 Abbott's FreeStyle Libre 2 continuous glucose monitoring system does not require fingersticks. Dr. Reddy's inks licensing deal with Gilead for remdesivir Dr. Reddy's will manufacture remdesivir, Gilead's investigational antiviral therapy used to treat COVID-19. Chiesi Group gets FDA blessing for new formulation of Ferriprox Chiesi Group’s Ferriprox (deferiprone) comes in twice a day 1,000-mg oral tablets, eliminating the midday dose. 2 Lilly drugs get new indications The FDA has given the green light for new indication's for Lilly's Cyramz, and Taltz. FDA approves new indication for AstraZeneca’s Farxiga AstraZeneca's Farxiga provides a treatment option for heart failure patients with reduced ejection fraction. Novartis gets FDA OK for Tabrecta Novartis' Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping. First Previous 28 29 30 31 32 Next Last
